Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

S. J. Jacobus; S. V. Rajkumar; M. Weiss; A. K. Stewart; E. A. Stadtmauer; N. S. Callander; L. M. Dreosti; M. Q. Lacy; R. Fonseca

doi:10.1038/BCJ.2016.55

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

S. J. Jacobus, S. V. Rajkumar, M. Weiss, A. K. Stewart, E. A. Stadtmauer, N. S. Callander, L. M. Dreosti, M. Q. Lacy, R. Fonseca

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Article number	e448
Journal	Blood cancer journal
Volume	6
Issue number	7
DOIs	https://doi.org/10.1038/BCJ.2016.55
State	Published - Jul 2016

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/BCJ.2016.55

Cite this

Jacobus, S. J., Rajkumar, S. V., Weiss, M., Stewart, A. K., Stadtmauer, E. A., Callander, N. S., Dreosti, L. M., Lacy, M. Q., & Fonseca, R. (2016). Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood cancer journal, 6(7), Article e448. https://doi.org/10.1038/BCJ.2016.55

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. / Jacobus, S. J.; Rajkumar, S. V.; Weiss, M. et al.
In: Blood cancer journal, Vol. 6, No. 7, e448, 07.2016.

Research output: Contribution to journal › Letter › peer-review

Jacobus, SJ, Rajkumar, SV, Weiss, M, Stewart, AK, Stadtmauer, EA, Callander, NS, Dreosti, LM, Lacy, MQ & Fonseca, R 2016, 'Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen', Blood cancer journal, vol. 6, no. 7, e448. https://doi.org/10.1038/BCJ.2016.55

Jacobus SJ, Rajkumar SV, Weiss M, Stewart AK, Stadtmauer EA, Callander NS et al. Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood cancer journal. 2016 Jul;6(7):e448. doi: 10.1038/BCJ.2016.55

@article{d97e4d4e38e845ba8660a09008d893ba,

title = "Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen",

author = "Jacobus, {S. J.} and Rajkumar, {S. V.} and M. Weiss and Stewart, {A. K.} and Stadtmauer, {E. A.} and Callander, {N. S.} and Dreosti, {L. M.} and Lacy, {M. Q.} and R. Fonseca",

note = "Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L Comis, MD, and Mitchell D Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under award numbers: CA180820, CA180794, CA21115, CA23318, CA66636, CA180790, CA13650, CA189956, CA35412, CA15488, CA180799 and CA21076.",

year = "2016",

month = jul,

doi = "10.1038/BCJ.2016.55",

language = "English (US)",

volume = "6",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

AU - Jacobus, S. J.

AU - Rajkumar, S. V.

AU - Weiss, M.

AU - Stewart, A. K.

AU - Stadtmauer, E. A.

AU - Callander, N. S.

AU - Dreosti, L. M.

AU - Lacy, M. Q.

AU - Fonseca, R.

N1 - Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L Comis, MD, and Mitchell D Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under award numbers: CA180820, CA180794, CA21115, CA23318, CA66636, CA180790, CA13650, CA189956, CA35412, CA15488, CA180799 and CA21076.

PY - 2016/7

Y1 - 2016/7

UR - http://www.scopus.com/inward/record.url?scp=85032440357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032440357&partnerID=8YFLogxK

U2 - 10.1038/BCJ.2016.55

DO - 10.1038/BCJ.2016.55

M3 - Letter

C2 - 27471864

AN - SCOPUS:85032440357

SN - 2044-5385

VL - 6

JO - Blood cancer journal

JF - Blood cancer journal

IS - 7

M1 - e448

ER -

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this